Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Oh gods of Penny Stocks let today be the day I unload all of my shares at .0002 .... amen! Please.
lol.... had to vent, I hate to be ripped off.
I can't believe the SEC ignores these scams! Damn, this hurts, you think that your playing the American dream and its all a con!
Up 100% and I still can't unload this garbage .... how does this work?
When they Brian and Daisey came to NY, they supposedly were in negotiation with a chain of supermarket stores "Compare Foods". I've yet to see ONE can of Koma, or any other BBDA product on the shelfs 0r on the isle. Can anyone please point me to a store in NY where I can find BBDA products? This is starting to stink like a typical pinky.
"Interest coming out of the woodworks" ... please clarify this, unlike those that fled to the woods, I'm left as a bag holder here. Can't sell a single share at .0002!!
I beleive that thier intent is to start marketing the products in Europe soon ... they still need European FDA like approval, but the European version of USA FDA regulations is less stringent.
Why so much emphasis on FDA, CTIC PIX can be sold in Europe and other countries without FDA approval.
Based on the 10k report the CEO has NO prior mining experience and the CFO is 24yrs old and studied French in college ... odd mix.
Big time what?
That numskull was given specific instructions and could not follow them ... he looks and even acts like Curly from the three stooges ... lol
ABC, I'm tip toeing around AMEL ... looks to good to be true ... read news letter today invoking Fords name ... I've got calls into Ford, if I get a yes to any kind of relationship, even if they meention that they know of AMEL, I'm in.
Never mind, I think you were referring to new coverage by SISM on AMEL ... I was not clear on your response to catty.
Did you get the report on AMEL from SISM? Are you insinuating that SISM supports the Ford buy-out?
European Regulatory Authorities Supportive of Pixantrone Marketing Authorization Application Submission to European Medicines Agency (EMEA)Font size: A | A | A1:30 AM ET 4/19/10 | PR Newswire
Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it met with and received feedback from the rapporteurs and the European Medicines Agency's (the "EMEA") medical reviewers regarding a proposed filing of a Marketing Authorization Application ("MAA") for pixantrone in the European Union to treat relapsed/refractory aggressive non-Hodgkin's lymphoma ("NHL"). The rapporteurs, who are assigned by the EMEA, are responsible for providing scientific advice on the evaluation of medicinal products. The feedback was supportive of filing on the basis of the PIX301 trial and the Company expects to submit the MAA in September 2010.
"Both the rapporteurs and medical reviewers felt that the totality of the efficacy data from the PIX301 trial including the complete response rate, overall response rate, progression-free survival and the trend in overall survival supports a MAA submission and review," said Jack Singer, M.D., Chief Medical Officer of the Company. "Relapsed/refractory aggressive NHL beyond second line therapy represents a significant unmet medical need in European Union and pixantrone has been granted orphan drug status in this indication. We will work diligently to move the application forward as quickly as possible," Singer added.
About Pixantrone
Pixantrone is a novel aza-anthracenedione that has distinct structural and physio-chemical properties that make its anti-tumor activity unique in this class of agents. Similar to anthracyclines, pixantrone inhibits Topo-isomerase II but unlike anthracyclines--rather than intercalation with DNA--, pixantrone alkylates DNA--forming stable DNA adducts, with particular specificity for CpG rich, hyper-methylated sites. These structural differences resulted in significantly enhanced anti-lymphoma activity compared to doxorubicin in preclinical models. In addition, the structural motifs on anthracycline-like agents that are responsible for the generation of oxygen free radicals and the formation of toxic drug-metal complexes have also been modified in pixantrone to prevent the binding of iron and perpetuation of superoxide production,--both of which are the putative mechanism for anthracycline induced acute cardiotoxicity. These novel pharmacologic differences may allow re-introduction of anthracycline like potency in the treatment of relapsed/refractory aggressive lymphoma without unacceptable rates of cardiotoxicity.
About Cell Therapeutics, Inc.
Headquartered in Seattle, the Company is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.
Sign up for email alerts and get RSS feeds at the Company's Web site, http://www.CellTherapeutics.com/investors_alert
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the Company's securities. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory, aggressive NHL as determined by the EMEA, that the Company may not submit the MAA in September 2010, that the EMEA may not accept the MAA, the Company's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, the Company does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
View data
Media Contact: Investors Contact:
Dan Eramian Ed Bell
T: 206.272.4343 T: 206.272.4345
C: 206.854.1200 Lindsey Jesch Logan
F: 206.272.4434 T: 206.272.4347
E: deramian@ctiseattle.com F: 206.272.4434
www.celltherapeutics.com/press_room E: invest@ctiseattle.com
www.celltherapeutics.com/investors
Media Contact: Investors Contact: Dan Eramian Ed Bell T: 206.272.4343 T: 206.272.4345 C: 206.854.1200 Lindsey Jesch Logan F: 206.272.4434 T: 206.272.4347 E: deramian@ctiseattle.com F: 206.272.4434 www.celltherapeutics.com/press_room E: invest@ctiseattle.com www.celltherapeutics.com/investors
SOURCE Cell Therapeutics, Inc.
Caught the tale end of the cc ... does not look bad ... still concerned about financing phase III, anyone have an opinion on other possible partners ... excluding Novartis? Anyone with biotech experience .... was this cc significanr, was news good, bad or indifferent?
Did I read the same PR? Thought the FDA gave CTIC a lifeline ... that requires CTIC to start new trial for PIX? No way they can complete trial by 2/23 .... Also, of concern is does CTIC have funding to carry through another trial period? Would be nice if big bro Novartis steps in at this juncture. imo.
This type of stuff happens all the time ... LLEG will still be in business once its settled. What the big deal?
ITS PENNEY LAND, Anything can and will happen .... money to be made, just don't get greedy!!
What the heck were they thinking (bianco Brothers) ... they should have known that not getting the 300+ participants would come back and bite them in the ass. Damn, real shame.
Nice close today .... could be effect of Chase conferance today? But Creppie makes a very valid point. Congrats on your other holdings.
Cyclone ... what are the chances of Novartis buying CTIC? I would say really good. imho ... what are your thoughts?
Who knows, maybe we have buys from these PR's coming in next two weeks ... it does take time to get the word out, seems like major media picking up on permit PR. Thanks for the post Matt.
Casa
Excellent read ... with our congressman and HLE connections we should be able to tap into these funds at some level. What do you think?
King, I would NOT mind one more shot at trip 0 ... I am confident that PPS will be in 52 week high with inking of new deals ... never mind Plant operational!! There is a core of investors whom own LLEG, but too few of us to keep pps high or at current level if we have a major sell off. But, I for one will pull the truck up and load up. Don't care if I wait two years more. As I've said before 20mil plus is my goal by plant live date, getting to 000 makes it soooo easy.
GLTA and Feliz Navidad, prospero ano y felicidad!!!
To any spanish speaking folks, sorry if I butchered the language.
Casa
He does it to everyone ... just click the ignore button on him if his posts annoy you.
I don't post much here ... the page is crappy and free??? this CEO releases way too many PRs, PR that does nothing for the pps. I'd like to see less and PR only when agreements have been signed and products on shelves ....
Casa
Is it important for me to see a pop in the pps .... YES, Am I in a race to make money ... YES, why else would I invest in a pinky? =D
I still believe that we will hear about one of the two deals next week prior to year end. imo
Dagnabbit ... could not pick at 1.13 .... there all day NOTHING??
Xanadu, we sure know how to pick winners don't we?
Just grabbed another 5k at 114 and 113 ... this thing is a steal at these prices ... imo. I beleive that Novartis will buy CTIC soon after Pix approval. Care to put a price on purchase? ALL IMHO.
Excellent read ...
discreet, you are def an assett to this board. Nice post.
Casa
I agree with you Sage .. know a few oil traders and commodities guys that have made alot of $$$ and no college. Who cares of MBB attended ivy league or no league! The point is he has developed a heck of a team around him ... true sign of a leader.
Penney, how much can you get for an extension cord?
Honestly, I can't figure it out either ... but I'm hoping the MM shake this down again ... get rid of the weak hands ... I really want to build my position here big time at the lowest possible pps. Call it greed or whatever, this is one of those "Once in a lifetime picks". I'm close to my pre run holdings of 6 mil and I want to be at 20mil + by the time the plant is operational.
So whay the fluctuation ... do institutions flip?
Sage, enjoy your Holidays and have a GREAT new year ... LLEG prosperous !!
Good point, One deal and PPA signed before year end ... niiiiice!